Ironwood Pharmaceuticals, Inc.

IRWD Healthcare Drug Manufacturers Specialty & Generic

Ironwood Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $296.2 million, down 15.7% from fiscal 2024. In the quarter to June 2026, revenue grew 32.6%, EPS grew 106.7%, free cash flow grew 486.7% and total debt was flat, each against the same quarter a year earlier.

3.50 0.27 −7.16%
Market cap
$623.0M
P/E
4.4×
Fwd P/E
2.8×
Dividend yield
—
F-score
5/9
Altman Z
−3.75
Beneish M
−4.20
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
6 6 5 6

+8 more TTM periods

ROE
(55.26%) (37.07%) (8.53%) (9.92%)
ROA
41.35% 26.83% 6.42% 7.27%
ROIC
101.61% 84.97% 57.33% 42.79%
Return on Tangible Assets
76.73% 103.05% 67.91% 81.55%
Average Days of Receivables
105.69 106.86 57.61 129.61
Free Cash Flow per Share
1.13 0.69 0.78 0.42
Free Cash Flow
185.56 112.21 127.01 67.65
Other line items

Show all line items

Columns are period end dates